EPR explores recent developments in stem cell therapies across several hard-to-treat diseases and how technology is transforming ATMP manufacture.
So far, 2023 has seen several major developments in stem cell-based therapies.
Stem cells have the ability to self-renew. Their potential to differentiate into cells of different tissues makes them particularly interesting for applications in regenerative medicine.1
Since the first therapy using stem cells was developed in 1957, only few stem cell-based therapies have entered the clinic1 as advanced therapy medicinal products (ATMPs).
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Yet over “the last two decades, rapid technological advances have led to the wide adoption of cell and gene therapy products for the treatment of a variety of disease states” according to Cundell et al. in a 2023 paper published in the Journal of Clinical Microbiology.
To facilitate this, regulation of cell therapies has transformed at pace in recent decades. In 2014, the first stem-cell therapy was recommended for approval in EU by the European Medicines Agency (EMA).2
the global stem cell therapy market is estimated to reach $928.6 million by 2031″
Looking ahead to the next decade, the global stem cell therapy market is estimated to reach $928.6 million by 2031. Between 2022-2031, autologous transplants are expected to hold the largest market share.3
Stem cell therapies for hard-to-treat diseases
HIV
Worldwide, nearly 38 million people live with HIV-1.4 Yet antiretroviral therapeutic interventions for disease management are only available to half of this population.5
In study results published in March 2023, stem cells from cord blood were shown to put the first mixed race, female patient with HIV into remission.
Using stem cells from cord blood rather than compatible adult donors, as has been done previously, increases the potential to cure HIV via stem cell transplantation in people of all racial backgrounds, according to the researchers.
Infectious disease expert Deborah Persaud of the Johns Hopkins University School of Medicine, highlighted the revolutionary potential of stem cell transplants: “If you’re going to perform a [stem cell] transplant as a cancer treatment for someone with HIV, your priority should be to look for cells that are CCR5-delta32/32 because then you can potentially achieve remission for both their cancer and HIV.”
Heart failure
In February 2023, the largest cell therapy trial to date for chronic heart failure due to low ejection fraction (EF), demonstrated the potential of mesenchymal precursor cells (MPCs) in addressing inflammation.
“For the first time, we’ve discovered that stem cells can successfully treat the inflammation that causes heart failure”
“For the first time, we’ve discovered that stem cells can successfully treat the inflammation that causes heart failure,” Dr Emerson C Perin, Medical Director at The Texas Heart Institute explained. The trial results are significant, Dr Perin told EPR, because the condition “currently is not addressed with medications, which treat the symptoms.”
The data revealed that the treatment gave patients a “58 percent reduced risk of heart attack or stroke, and the benefits rose to 75 percent in patients with high inflammation,” Dr Perin noted.
The stem cell therapy offered these outcomes because “reduced inflammation resulting from the activation of MPCs may decrease plaque instability, which is what leads to heart attacks and strokes.” Dr Perin highlighted the results as an “important milestone in the field of cardiac cell therapy”.
Multiple sclerosis
Results from an Italian study published in Neurology in December 2022 showed that autologous haematopoietic stem cell transplants have potential for delaying disability in active secondary progressive multiple sclerosis (MS).
“Haematopoietic stem cell transplants were associated with a slowing of disability progression and a higher likelihood of disability improvement compared to other therapies,” Dr Matilde Inglese, author of the study from the University of Genoa, Italy, explaining the study’s findings.
Over the ten-year-long, retrospective study, 79 people were evaluated. After five years, 19 percent of people that received stem cell transplants experienced less disability than at the start of the study. This was compared to four percent of patients who took medication.
Parkinson’s
In February 2023, a milestone was achieved in treating Parkinson’s disease (PD). Developed at Lund University in Sweden, a new stem cell therapy transplant was given to a human for the first time.
Parkinson’s occurs when an area of the brain loses dopamine-producing nerve cells. This chemical helps to regulate body movement and loss of these nerve cells results in reduced dopamine levels in the brain.
As part of the STEM-PD clinical trial, eight patients were enrolled to receive the stem cell transplant, delivered into the brain. Designed to replace the lost dopamine cells, the stem cell therapy delivers healthy dopamine cells: ventral midbrain dopaminergic progenitor cells manufactured from stem cells: clinical-grade hESC line RC17.
Participants will be evaluated initially after the first 12 months following transplantation, with any changes in clinical effects being assessed at 36 months post-transplantation.
Other organisations who collaborated in the trial were Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.
Automating stem cell manufacture
The Medicines and Healthcare products Regulatory Agency (MHRA) announced in March 2023 that its UK Stem Cell Bank was testing automated robotic technology for growing stem cells.
“The UK is only the second country where this technology has been tested,” explained Steve Barclay, UK Health and Social Care Secretary.
Over 12 months, the robot will be tested for its efficacy in manufacturing stem cells. Previously, the availability of cell-based therapies “has been limited because they are often very difficult to manufacture,” according to the MHRA’s Chief Scientific Officer, Marc Bailey.
For instance, despite limitations with mass production, high manufacturing cost, and contamination6, human (h)MPCs are the most promising pharmaceutical multipotent stem cells.6 Specifically, using closed automated devices is crucial in enabling their efficient expansion and validation.5
The innovative stem cell robot being tested by the UK Stem Cell Bank could change this, making the “manufacturing process much easier” due to its potential for reducing human error and producing a “more consistent final product,” Bailey added. Ultimately, this will result in “safer and more effective treatments” for Parkinson’s and other diseases.
About the Author
Catherine Eckford is Editorial Assistant at European Pharmaceutical Review.
References
Zhang K, Cheng K. Stem cell-derived exosome versus stem cell therapy. Rev. Bioeng. 2023.
First stem-cell therapy recommended for approval in EU. [Internet] European Medicines Agency. 2014. Available from: https://www.ema.europa.eu/en/news/first-stem-cell-therapy-recommended-approval-eu.
Stem cell therapy Market: Global Opportunity Analysis and Industry Forecast, 2021-2031. [Internet] Allied Market Research. 2022. [cited 2023May]. Available from: https://www.alliedmarketresearch.com/stem-cell-therapy-market-A10952.
Jankovic M G, Stojkovic M, Bojic S et al. Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses. Res. Transl. Med. 2023; 71(2): 103393.
Dr. Perin, this discovery is incredibly promising, as it addresses a major gap in heart failure treatment. Traditional heart failure medications largely focus on alleviating symptoms—like fluid retention or blood pressure control—without directly targeting the underlying inflammation that can drive the disease.
impressive reduction in risk—58% overall, and even up to 75% for patients with high inflammation—highlights a potential breakthrough in how we manage and treat heart failure.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Dr. Perin, this discovery is incredibly promising, as it addresses a major gap in heart failure treatment. Traditional heart failure medications largely focus on alleviating symptoms—like fluid retention or blood pressure control—without directly targeting the underlying inflammation that can drive the disease.
impressive reduction in risk—58% overall, and even up to 75% for patients with high inflammation—highlights a potential breakthrough in how we manage and treat heart failure.